Selskabets formål er at drive virksomhed med udvikling og salg af produkter og serviceydelser til brug indenfor drug discovery og anden i forbindelse dermed stående virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 130.6 mio. | -17.2 mio. | 97.9 mio. | -4.9 mio. | 82 | |
CVR: 26186676
Previous names: VISIOPHARM ApS
Compared to 6.293 companies in Computerkonsulentbistand og forvaltning af computerfaciliteter
Comparison is based on industry median values
Per Fredrik Thorell joined the board
Evis Hursever joined the board
Andrew James Thomson joined the board
Susanne Høiberg left the board
Thomas Weilby Knudsen left the board
Claus Henrik Berner Møller left the board
Martin Bonde left the board
Jeannett Hvidkjær left the board
Patrik Olof Dahlén left the board
Morten Frost Norgreen left the board
Companies in the same industry and area
CVR 26699339
CVR 33364334
CVR 28099223
CVR 44909995
CVR 29529027
The financial health of VISIOPHARM A/S shows significant challenges, with consistent losses over the past five years. Revenue has fluctuated slightly, peaking at 135,974,000 DKK in 2022 but declining to 130,617,000 DKK in 2025, while profit margins remain negative, culminating in a loss of 17,223,000 DKK in 2025. Equity has deteriorated sharply from 59,406,000 DKK in 2021 to -4,949,000 DKK in 2025, indicating a concerning trend of increasing financial instability. The company's position within the computer consulting and facility management industry appears precarious, with ongoing profitability issues and a declining equity base raising concerns about its sustainability and growth potential.
AI-generated summary
companydata.dk